VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
GYRE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
GYREGyre Therapeutics, Inc.
$5.90$539M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGYREQuarterly Financials

Gyre Therapeutics, Inc. (GYRE) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Gyre Therapeutics, Inc. (GYRE) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

GYRE Income Statement

Quarterly statement

GYRE Income Statement

Gyre Therapeutics, Inc. (GYRE) annual income statement — 22-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21Q3'21
Sales/Revenue29.11M22.52M37.2M30.56M26.77M22.06M27.87M25.49M25.23M27.17M27.15M32.04M29.33M24.93M28.48M29.17M0794K2.44M2.3M
Revenue Growth %8.72%2.09%33.45%19.92%6.13%-18.82%2.67%-20.45%-13.99%8.99%-4.67%9.85%-3039.92%1067.14%1168.81%-100%-45.88%20.14%157.45%
Cost of Goods Sold2.21M1.23M1.74M1.63M1.15M894K1.18M958K770K979K1.25M1.18M1.08M1.13M1.36M1.39M67K798K2.45M2.39M
COGS % of Revenue7.59%5.45%4.69%5.33%4.3%4.05%4.22%3.76%3.05%3.6%4.6%3.7%3.67%4.51%4.78%4.77%-100.5%100.57%104.05%
Gross Profit26.9M21.29M35.45M28.94M25.62M21.16M26.7M24.53M24.45M26.19M25.9M30.86M28.25M23.81M27.12M27.78M-67K-4K-14K-93K
Gross Margin %92.41%94.55%95.31%94.67%95.7%95.95%95.78%96.24%96.95%96.4%95.4%96.3%96.33%95.49%95.22%95.23%--0.5%-0.57%-4.05%
Gross Profit Growth %4.98%0.6%32.8%17.96%4.76%-19.2%3.08%-20.51%-13.44%10.03%-4.5%11.09%42267.16%595250%193796.26%29968.35%-28.85%69.23%68.89%-416.67%
Operating Expenses41.26M30.65M35.33M22.01M23.45M18.89M26.1M20.3M21.19M18.12M117.53M18.09M23.28M17.14M22.52M23.18M5.65M14.7M20.3M25.14M
OpEx % of Revenue141.76%136.09%94.99%72.02%87.59%85.64%93.64%79.63%84.02%66.69%432.92%56.47%79.37%68.76%79.06%79.45%-1851.01%831.93%1093.34%
Selling, General & Admin21.62M21.36M30.52M19.65M20.02M15.8M22.32M17.52M17.84M15.94M26.52M15.09M19.71M14.51M22.28M22.7M3.84M4.99M4.16M4.87M
SG&A % of Revenue74.29%94.84%82.05%64.28%74.79%71.61%80.08%68.75%70.72%58.66%97.68%47.08%67.2%58.19%78.24%77.8%-628.97%170.66%211.79%
Research & Development19.14M6.74M4.82M2.36M3.42M3.1M3.71M2.77M3.35M2.18M4.57M3.01M3.57M2.63M6.22M6.28M1.8M9.7M16.14M20.27M
R&D % of Revenue65.75%29.92%12.95%7.73%12.79%14.03%13.32%10.89%13.3%8.03%16.83%9.39%12.17%10.57%21.83%21.54%-1222.04%661.27%881.56%
Other Operating Expenses502K1000K01K1K066K0001000K000-1000K-1000K00-20K0
Operating Income-14.36M-9.36M120K6.92M2.17M2.27M597K4.23M3.26M8.07M-91.63M12.76M4.97M6.66M4.6M4.6M-5.71M-14.7M-20.31M-25.23M
Operating Margin %-49.35%-41.54%0.32%22.66%8.11%10.3%2.14%16.61%12.93%29.7%-337.53%39.84%16.96%26.73%16.16%15.77%--1851.51%-832.5%-1097.39%
Operating Income Growth %-761.58%-511.57%-79.9%63.6%-33.45%-71.84%100.65%-66.84%-34.42%21.11%-2091.35%177.39%187.03%145.33%122.65%118.24%71.3%34.48%-7.81%-56.7%
EBITDA-14.3M-8.68M815K7.57M2.81M2.81M1.07M4.71M3.5M8.49M-91.32M12.97M5.29M6.95M4.83M4.84M-5.65M-14.59M-20.2M-25.14M
EBITDA Margin %-49.12%-38.56%2.19%24.78%10.5%12.73%3.83%18.47%13.88%31.23%-336.39%40.47%18.04%27.88%16.97%16.6%--1837.28%-827.79%-1093.69%
EBITDA Growth %-608.43%-409.22%-23.69%60.91%-19.66%-66.91%101.17%-63.7%-33.86%22.1%-1989.63%167.72%193.7%147.64%123.93%119.26%71.57%34.85%-7.46%-56.58%
D&A (Non-Cash Add-back)66K672K695K649K641K535K471K474K238K415K308K202K318K286K231.39K241.56K67K113K115K85K
EBIT-14.43M-9.24M-66K7.63M2.17M4.63M663K3.93M6.04M12.48M-5.19M12.76M4.97M6.66M-1.38M-1.2M51.63M7.95M-20.33M-25.24M
Net Interest Income740K0509K200K300K200K346K523K350K328K0283K0184K-549K282K0-13.68K4K7K
Interest Income740K0509K200K300K200K346K523K350K328K0283K0184K167K283K102K04K7K
Interest Expense00000000000000716K1K102K13.68K00
Other Income/Expense-71K118K-186K704K66K2.36M109K-303K2.77M4.41M-8.65M-1.58M880K-393K-5.74M-5.56M57.35M19.56M-16K-9K
Pretax Income-14.43M-9.24M-66K7.63M2.24M4.63M772K3.93M6.04M12.48M-100.28M11.19M5.85M6.27M-1.14M-962.3K51.63M4.86M-20.33M-25.24M
Pretax Margin %-49.59%-41.02%-0.18%24.96%8.36%21.01%2.77%15.42%23.92%45.93%-369.38%34.92%19.96%25.15%-4.01%-3.3%-611.47%-833.16%-1097.78%
Income Tax-164K-621K1.3M1.69M662K901K203K1.07M1.5M2.55M699K3.68M2.08M2.05M1.33M1.37M0-182K00
Effective Tax Rate %1.14%6.72%-1969.7%22.19%29.58%19.44%26.3%27.33%24.81%20.4%-0.7%32.87%35.6%32.75%-116.84%-142.36%0%-3.75%0%0%
Net Income-10.61M-8.62M-1.72M3.61M442K2.7M-99K1.12M3.53M7.53M-101.01M3.98M1.85M2.24M-3.48M-3.34M51.63M5.04M-20.33M-25.24M
Net Margin %-36.44%-38.26%-4.63%11.81%1.65%12.23%-0.36%4.41%13.99%27.72%-372.06%12.41%6.32%9%-12.22%-11.44%-634.39%-833.16%-1097.78%
Net Income Growth %-2499.32%-419.35%-1640.4%221.17%-87.47%-64.18%99.9%-71.73%90.39%235.65%-2802.83%219.1%-96.41%-55.45%82.88%86.77%359.09%122.45%-7.52%-57.41%
Net Income (Continuing)-14.27M-8.62M-1.37M5.94M1.58M3.73M569K2.86M4.54M9.94M-100.98M7.51M3.77M4.22M-2.47M-2.33M51.63M5.04M-20.33M-25.24M
Discontinued Operations00000000000000000000
Minority Interest34.56M35.68M36.25M35.49M37.42M36.18M35.08M35.3M32.99M32.13M29.78M00029.7M00000
EPS (Diluted)-0.12-0.10-0.020.030.000.00-0.000.010.030.07-0.680.050.080.08-0.05-0.050.080.08-0.65-0.80
EPS Growth %---249%-93.49%-94.14%99.5%-80.73%-57.64%-4.3%-1143.14%194.88%5.42%-4.24%91.58%93.16%111.83%110.14%23.53%-9.59%
EPS (Basic)-0.12-0.10-0.020.040.010.03-0.000.010.040.09-0.680.050.080.08-0.06-0.050.080.08-0.65-0.80
Diluted Shares Outstanding100.64M91.34M102.94M102.7M102.7M101.97M102.29M102.64M104.33M102.59M76.6M76.6M70.09M70.09M63.59M61.05M62.94M62.91M31.42M31.38M
Basic Shares Outstanding100.64M91.32M91.16M89.12M89.12M86.42M85.09M85.64M85.5M83.27M76.6M76.6M69.95M69.95M63.3M61.05M62.94M62.91M31.42M31.38M
Dividend Payout Ratio--------------------